Last reviewed · How we verify
Visen Pharmaceuticals (Shanghai) Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| daily hGH | daily hGH | phase 3 | ||||
| TransCon PTH | TransCon PTH | phase 3 | PTH analogue | PTH receptor | Bone disorders |
Therapeutic area mix
- Bone disorders · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Visen Pharmaceuticals (Shanghai) Co., Ltd.:
- Visen Pharmaceuticals (Shanghai) Co., Ltd. pipeline updates — RSS
- Visen Pharmaceuticals (Shanghai) Co., Ltd. pipeline updates — Atom
- Visen Pharmaceuticals (Shanghai) Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Visen Pharmaceuticals (Shanghai) Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/visen-pharmaceuticals-shanghai-co-ltd. Accessed 2026-05-18.